Literature DB >> 14707707

Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.

Marilyn J Manco-Johnson1, Rhonda Knapp-Clevenger.   

Abstract

Severe genetic protein C deficiency is rare and is associated with severe, often fatal thrombosis. The authors report the use of recombinant activated protein C (APC) to treat an episode of purpura fulminans (PF) in a teenage girl with severe protein C deficiency who had developed anaphylaxis to fresh-frozen plasma that was given in the past to treat recurrent episodes of PF. Concomitant with an infusion of APC, 20 microg/kg/h for 10 hours, a d-dimer level that was markedly positive (6,450 ng/mL) prior to the onset of PF decreased to 847 ng/mL following the APC. The teenager was treated with heparin along with warfarin for four days until the INR was more than 3.5 and the d-dimer level was less than 230 ng/mL. At the end of the APC infusion all skin lesions of PF were resolved. There were no adverse reactions to APC. APC was safe and effective for treatment of PF in severe genetic protein C deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14707707     DOI: 10.1097/00043426-200401000-00008

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

Review 1.  Issues concerning the laboratory investigation of inherited thrombophilia.

Authors:  Armando Tripodi
Journal:  Mol Diagn       Date:  2005

Review 2.  Recombinant human activated protein C for severe sepsis in neonates.

Authors:  Ranjit I Kylat; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

3.  Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Authors:  Sabine Kroiss; Manuela Albisetti
Journal:  Biologics       Date:  2010-03-24

4.  Empiric treatment of protracted idiopathic purpura fulminans in an infant: a case report and review of the literature.

Authors:  Fima Macheret; Kavitha N Pundi; Eileen M Broomall; Dawn M Davis; Vilmarie Rodriguez; Chad K Brands
Journal:  J Med Case Rep       Date:  2011-05-23

5.  Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

Authors:  Jean-Louis Vincent; Simon Nadel; Demetrios J Kutsogiannis; R T Noel Gibney; S Betty Yan; Virginia L Wyss; Joan E Bailey; Carol L Mitchell; Samiha Sarwat; Stephen M Shinall; Jonathan M Janes
Journal:  Crit Care       Date:  2005-05-17       Impact factor: 9.097

6.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.